FDA Expands Recall of EpiPens

Comments (0)

Mylan, the maker of EpiPens, announced a recall in March 2017 for units sold in Australia, due to a potentially defective part that could result in the device failing to activate. The FDA recently announced that the recall has been expanded to include additional lots sold in the U.S.  Certain lots sold between December 2015 and July 2016 have been recalled. Any injectors sold outside that time frame do not need to be replaced.

EpiPens are used to provide emergency epinephrine to allergy patients who are experiencing a life-threatening allergy attack. These patients may have trouble breathing and wheezing, low blood pressure, and very itchy skin. The injector delivers a dose of epinephrine, which helps relax the lungs and improve breathing.

The recall occurred after the company received two reports of the auto-injectors failing to activate because of a problem with one of the components of the pen. Since EpiPens are often used in emergencies, if the injectors do not work the users could suffer serious health risks. The company says it will replace the recalled devices for free.

Earlier this month, a class action lawsuit was filed against Mylan over EpiPens. The lawsuit claims that Mylan took advantage of consumers by increasing the list prices of the devices 17 times since 2007. The prices began at $90 and were recently $608. Plaintiffs say that the company benefitted from the scheme and paid high kickbacks to pharmacy benefit managers.

When a drug or a medical device fails, consumers can be seriously harmed. In that situation, the consumer can sue the drug company or medical device company, and may be entitled to damages. Call the Houston drug recall attorneys at Kennedy Hodges at 855-947-0707. We can help. Call us today to learn more or to schedule a free consultation on your case, or visit us on YouTube to learn more. 

Be the first to comment!

Post a Comment

To reply to this message, enter your reply in the box labeled "Message", hit "Post Message."


Email:* (will not be published)


Notify me of follow-up comments via email.